[Special Stock] Kolon TissueGene Rises for Two Consecutive Days After Trading Resumption

[Asia Economy Reporter Kwon Jae-hee] Kolon TissueGene, which resumed trading after 3 years and 5 months, has continued its upward trend for two consecutive days.

As of 10:14 AM on the 26th, Kolon TissueGene is trading at 21,750 KRW, up 4.32% compared to the previous trading day.

During the session, Kolon TissueGene rose as much as 17.51% to 24,500 KRW before giving up some of the gains.

On the first day of resumed trading, the previous day (25th), it closed at 20,850 KRW, up to the price limit increase of 29.91% from the opening price.

The Korea Exchange announced that after holding a review by the Corporate Evaluation Committee on the 24th and the KOSDAQ Market Committee, it decided to maintain Kolon TissueGene's listing.

Previously, Kolon TissueGene's stock trading was suspended since May 2019 after the Ministry of Food and Drug Safety confirmed the cancellation of the product approval for the new drug 'Invossa-K' due to controversy over its components, leading to a substantive review of its listing eligibility by the exchange.